Document Detail


Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer.
MedLine Citation:
PMID:  21656738     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Kallikrein-related peptidase 6 (KLK6) encodes a trypsin-like serine protease that is up-regulated in several cancers, although the putative functions of KLK6 in cancer have not been elucidated. In the current study, overexpression of KLK6 was identified in colon cancer, and the possibility that KLK6 may be a suitable candidate as a tumor marker was examined.
METHODS: Messenger RNA (mRNA) transcript levels and protein up-regulation of KLK6 in colon cancer tissues was examined using reverse transcriptase-polymerase chain reaction, immunohistochemistry, and clinicopathologic analyses. Cell proliferation, invasiveness, and antiapoptotic activity were determined in colon cancer cells that were transfected with small-interfering RNA (siRNA) of KLK6.
RESULTS: KLK6 mRNA was up-regulated significantly in tumor tissues compared with nontumor regions. KLK6 protein was strongly expressed in adenocarcinomas but was not expressed in normal mucosa or in premalignant dysplastic lesions. Sera from patients with colon cancer revealed an increase in KLK6 secretion (0.25 μg/mL; P = .031) compared with noncancer cells (0.19 μg/mL). Clinicopathologic and immunohistochemical studies of 143 patients with colon cancer revealed a significant correlation between KLK6 expression and Dukes disease stage (P = .005). High KLK6 expression was associated significantly with shorter overall (P = .001) and recurrence-free survival (P = .001). The rates of proliferation and invasiveness were decreased by 50% in cells that were transfected with KLK6 siRNA. The overexpression of KLK6 led to decreased activity of the E-cadherin promoter.
CONCLUSIONS: KLK6 was up-regulated significantly in tissues and sera from patients with colon cancer and was associated closely with a poor prognosis, suggesting that KLK6 may be used as a potential biomarker and a therapeutic target for colon cancer. Cancer 2011;. © 2010 American Cancer Society.
Authors:
Jong-Tae Kim; Eun Young Song; Kyung-Sook Chung; Min Ah Kang; Jae Wha Kim; Sang Jick Kim; Young Il Yeom; Joo Heon Kim; Kyo Hyun Kim; Hee Gu Lee
Related Documents :
21803568 - Spatial variation in stage distribution in colorectal cancer in the netherlands.
21677748 - Microenvironmental regulation of stem cells in intestinal homeostasis and cancer.
21618248 - Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, bu...
21831168 - Comparative effectiveness of different chemotherapeutic regimens on survival of people ...
23632818 - The increased risk of colon cancer due to cigarette smoking may be greater in women tha...
2909758 - Allium vegetables and reduced risk of stomach cancer.
Publication Detail:
Type:  Journal Article     Date:  2010-12-23
Journal Detail:
Title:  Cancer     Volume:  117     ISSN:  1097-0142     ISO Abbreviation:  Cancer     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-06-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2608-19     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 American Cancer Society.
Affiliation:
Medical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Disparities in the application of adjuvant radiotherapy after breast-conserving surgery for early st...
Next Document:  A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetasta...